{
    "nctId": "NCT03535961",
    "briefTitle": "Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer",
    "officialTitle": "Phase II Single Arm Study of Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 32,
    "primaryOutcomeMeasure": "objective response rate(ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age between 18 and 75 year-old women; HER2 negative(immunohistochemistry or fluorescence in situ hybridization);\n* ECOG score: 0-1, expected survival time \u2265 3months;\n* Pathologically or cytologically confirmed breast cancer;\n* Anthracycline- / taxane- pretreated (adjuvant, neoadjuvant) breast cancer patients who have failed from 1-2 standard chemotherapies after recurrence and metastasis;\n* According to RECIST 1.1, exist at least \u22651 measurable lesion(CT \\>1cm\uff0cother examination \\>2cm);\n* The patients have enough organ function. The laboratory test indexes must comply with the following requirements:\n\n  * Blood routine: neutrophil\u22651.5G/L, platelet count \u226580G/L, hemoglobin \u226590g/L\n  * Liver function: serum bilirubin \u2264 1.5 times the upper limit of normal value; ALT and AST\u22642.5 times the upper limit of normal value; ALT and AST\u22645 times the upper limit of normal value when liver metastasis\n  * Renal function: serum creatinine \u2264 1.0times the upper limit of normal value, creatinine clearance \\>50ml/min\uff08Cockcroft-Gault formula)\n* Women of child-bearing age should be carried out pregnancy test (serum or urine) within 7 days before recruit, the results should be negative; and are willing to adopt the appropriate methods of contraception during the trial and 8 weeks after last administration\uff1b\n* Can swallow oral drugs;\n* The patients have good compliance to the therapy and follow-up to be scheduled and are able to understand the study protocol and sign the Informed Consent Form.\n\nExclusion Criteria:\n\n* The patients in pregnancy or lactation growth period and did not take effective contraception;\n* The patients who received \u22653 chemotherapies\uff08Do not include endocrine therapy\uff09after recurrence and metastasis; involved in other clinical trials four weeks prior to the start of the study;\n* The patients with a variety of factors that affect the oral administration and absorption of drugs;\n* The patients previously received anti-VEFG of anti-VEGFR therapies;\n* The patients with rapid progression of viscera invasion(liver lesion \\>1/2 viscera area or liver dysfunction);\n* The patients have uncontrollable mental illness.\n* The patients who had serious adverse effect to oral etoposide or were allergic to etoposide.\n* The patients who have only bone metastasis without other measurable lesion;\n* The patients experience severe cardiovascular diseases;\n* The patients experience severe upper gastrointestinal ulcer or malabsorption syndrome.\n* Abnormal bone marrow functions(neutrophil\\<1.5G/L, platelet count \\<75G/L, hemoglobin \\<90g/L);\n* Abnormal renal function(serum creatinine \\> 1.5 times the upper limit of normal value);\n* Abnormal liver function(serum bilirubin \u2264 1.5 times the upper limit of normal value);\n* The patients have uncontrollable brain metastasis;\n* The patients do have good compliance to the therapy.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}